Abbott Finds Lipid Lowering Partner With Kos Acquisition
This article was originally published in The Pink Sheet Daily
Executive Summary
Candidates would be competitors to Pfizer's Lipitor/torcetrapib combination.
You may also be interested in...
M&A Fireworks: Shire Buys Jerini For €328 Million
Jerini secures a hefty payout, despite FDA deeming HAE candidate Firazyr “not approvable.”
M&A Fireworks: Shire Buys Jerini For €328 Million
Jerini secures a hefty payout, despite FDA deeming HAE candidate Firazyr “not approvable.”
Riding On Humira Sales, Abbott Aims For Dominance In Lipid Management Market
Product launches and Humira label expansions will compensate for Depakote generics entering the market in July, CEO White says.